{"id":"hyperacute-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine uses a weakened or inactivated form of a disease-causing agent to trigger an immune response, which can provide long-term protection against future infections.","oneSentence":"The HyperAcute vaccine works by stimulating the body's immune system to recognize and fight specific diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:23:21.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT02460367","phase":"PHASE1","title":"Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent","enrollment":16},{"nctId":"NCT00105053","phase":"PHASE1, PHASE2","title":"Vaccine Treatment for Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2005-03","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT00420732","phase":"PHASE2","title":"Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2007-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT00569387","phase":"PHASE2","title":"Vaccine Study for Surgically Resected Pancreatic Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2007-12","conditions":"Pancreatic Cancer","enrollment":73},{"nctId":"NCT00255827","phase":"PHASE1, PHASE2","title":"Vaccine Treatment for Surgically Resected Pancreatic Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2005-11","conditions":"Pancreatic Cancer","enrollment":7},{"nctId":"NCT01774578","phase":"PHASE2, PHASE3","title":"Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-02","conditions":"Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent","enrollment":135},{"nctId":"NCT00090480","phase":"PHASE1, PHASE2","title":"Vaccine Treatment for Advanced Breast Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2004-08","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00073398","phase":"PHASE1, PHASE2","title":"Vaccine Treatment for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2003-11","conditions":"Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma","enrollment":54},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT00614601","phase":"PHASE2","title":"Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2008-01","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT00300612","phase":"PHASE1, PHASE2","title":"Vaccine Treatment for Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2006-03","conditions":"Malignant Melanoma","enrollment":6},{"nctId":"NCT02405585","phase":"PHASE2","title":"Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2015-04","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable","enrollment":10},{"nctId":"NCT01072981","phase":"PHASE3","title":"Immunotherapy Study for Surgically Resected Pancreatic Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2010-04","conditions":"Pancreatic Cancer","enrollment":722},{"nctId":"NCT00746746","phase":"PHASE2","title":"A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma","status":"UNKNOWN","sponsor":"Ochsner Health System","startDate":"2008-06","conditions":"Melanoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HyperAcute vaccine","genericName":"HyperAcute vaccine","companyName":"Ochsner Health System","companyId":"ochsner-health-system","modality":"Biologic","firstApprovalDate":"","aiSummary":"The HyperAcute vaccine works by stimulating the body's immune system to recognize and fight specific diseases. Used for COVID-19 prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}